相关实验视频
Updated: Jul 14, 2025

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
在临床缓解期的性结肠炎患者中,基于便中calprotectin水平的梅萨拉剂量修改
Gisela Piñero1, Míriam Mañosa2, Margalida Calafat2
1Servicio de Aparato Digestivo, Hospital Univrsitari Germans Trias i Pujol, Badalona, Barcelona, España; Servicio de Gastroenterología, Hospital Provincial del Centenario, Rosario, Argentina.
监测便中calprotectin (FC) 水平,以调整在性结肠炎 (UC) 患者的梅萨拉剂量是缓解的安全策略. 这种方法有助于维持临床缓解,复发率在两年内约为20%.
科学领域:
- 胃肠病学 胃肠病学
- 临床医学 临床医学
- 炎症性肠道疾病研究研究
背景情况:
- 便calprotectin (FC) 是性结肠炎 (UC) 活动和复发预测的可靠标志物.
- 目前的临床实践缺乏根据FC水平调整梅萨拉剂量的指导方针.
研究的目的:
- 在UC患者中,根据FC水平指导调整梅萨拉剂量的临床有用性.
- 评估该策略在维持临床缓解方面的长期有效性.
主要方法:
- 追溯性,单中心研究,涉及UC患者在梅萨拉的临床缓解中.
- 根据FC水平调整 (增加或减少) 患者的梅萨拉剂量.
- 主要终点是持续维持临床缓解.
主要成果:
- 在降低梅萨拉剂量 (DOWN) 组中,28%的患者需要救援治疗,无复发2年生存率为82%.
- 在梅萨拉剂量增加组 (UP) 中,29%的患者需要救援治疗,无复发2年生存率为72%.
- 两种剂量修改策略都表明可以接受的长期缓解维持.
结论:
- 根据FC监测修改梅萨拉剂量是UC缓解期患者的安全和潜在有效策略.
- 这种方法可以帮助个性化治疗,防止临床复发.
- 需要进一步的前性研究来证实这些发现.
更多相关视频
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF